Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient

Kyo Ik Mo, Ki Ho Kim, Young Jin Seo, Kyung Seop Lee From the Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea In some patients with prostate cancer and who manifest disease progression during maximal androgen blockade (MAB) therapy, discontinuation of antiandrogen treatment might result in a significant fall in the level of serum prostate-specific antigen (PSA), and this is often correlated with clinical improvement (antiandrogen withdrawal syndrome). However, a decline in the PSA level after the withdrawal of estramustine phosphate is extremely rare. We report here on a case of dramatic decline in the PSA level after withdrawal of estramustine phosphate in a patient with hormone refractory prostate cancer. (Korean J Urol 2007;48:751-753) 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏